In health economics and outcomes research (HEOR) and epidemiologic studies, claims data alone leave researchers without essential information such as: Body mass index (BMI) or weight trajectory to identify obesity thresholds or track improvement A1c and lipid panels to assess cardiometabolic change Liver and kidney markers such as ALT, AST, and eGFR to evaluate comorbidities like MASH or nephropathy Physician notes that document adherence barriers, recommended dosing schedules, or dietary guidance These gaps in claims mean that researchers are missing many aspects of the patient journey (Figure 1)
The agreement of low lean mass with obesity using different definitions and its correlation with hyperuricemia
Medical companies maintain all the patent protections that prevent the other manufacturers from creating a similar generic version at scale, even if semaglutide is the major and active ingredient
The diabetes drug has seen a dramatic uptick in popularity over the past few months due to the weight loss and impulse suppression effects that it has on its users
is a board-certified cardiologist and certified psychotherapist with more than thirtyfive years of clinical experience treating, preventing and reversing heart disease
Suspiciously cheap peptides often contain impurities, incorrect sequences, or degraded material that compromises both safety and efficacy
.png)
